The role of conjugation processes and linking agents in the preparation of molecular/particulate conjugates: A review

S.T.P. Pharma Sciences

Volumn 9, Issue 4, 1999, Pages 307-319

  Cattel, L ^a   Dosio, F ^b   Brusa, P ^a   Arpicco, S ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

Antitumoral agents; Conjugates; Immunoliposome; Immunotoxin; Linking agents

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOLIPOSOME; IMMUNOTOXIN; LECTIN; TRANSFERRIN;

ANTINEOPLASTIC ACTIVITY; CYTOTOXICITY; DRUG CONJUGATION; DRUG DESIGN; DRUG MARKETING; PARTICULATE MATTER; REVIEW; TARGET CELL;

EID: 0032861604     PISSN: 11571489     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (102)

1. SEZAKI H. and HASHIDA M. - Macromolecules as drug delivery systems. - In: Direct Drug Delivery: A Multidisciplinary Problem, R.T. Borchardt, A.J. Repta and V.J. Stella Eds., Humana Press, Clifton, 1985, pp. 189-208.
2. MAGERSTÄDT M. - Antibody Conjugates and Malignant Disease. - CRC Press, Boca Raton 1991, 1-214.
3. POZNANSKY M.J. and JULIANO R.L. - Biological approaches to the controlled delivery of drugs: a critical review. - Pharmacol. Rev., 36, 277-334, 1984.
4. MAEDA H., SEYMOUR L.W. and MIYAMOTO Y. - Conjugates of anticancer agents and polymers: advantages of macromoleculartherapeutics in vivo. - Bioconjugate Chemistry, 3, 351-362, 1992.
5. BYRN S.R. and STOWELL J.G. - Drug targeting using conjugates: the importance of pharmaceutical chemistry. - J. Drug Targ., 3, 239-241, 1995.
6. CATTEL L., BRUSA P. and DOSIO F. - Immunoconjugates. -Chimica Oggi (Chemistry Today), 6, 51-59, 1989.
7. GHETIE M.A. and VITETTA E.S. - Recent developments in immunotoxin therapy. - Current Opinion in Immunology, 6, 707-714, 1994.
8. WAWRZYNCZAK E.J. - Rational design of immunotoxins: current progress and future prospect. - Anti-Cancer Drug Design, 7, 427-441, 1992.
9. SHEN T.Y. - Drug delivery via cell-surface receptors. - In: Direct Drug Delivery: A Multidisciplinary Problem, R.T. Borchardt, A.J. Repta and V.J. Stella Eds., Humana Press, Clifton, 1985, pp. 231-245.
10. WADHWA M.S. and RICE K.G. - Receptor mediated glycotargeting. - J. Drug Targ., 3, 111-127, 1995.
11. HASHIDA M., HIRABAYASHI H., NISHIKAWA M. and TAKAKURA Y. - Targeted delivery of drugs and proteins to the liver via receptor-mediated endocytosis. - J. Contr. Rel., 46, 129-137, 1997.
12. SASAKI K., KOHGO Y., KATO J., KONDO H. and NIITSU Y. -Intracellular metabolism and cytotoxicity of transferrin-neocarzinostatin conjugates of differing molar ratios. - Japanese Journal of Cancer Research, 84, 191 -196, 1993.
13. SINGH V. and CURTISS R. - Hormonotoxins. The role of positive charge of lysine residue on the immunological, biological and cytotoxic properties of ovine lutropin-S-S-gelonin conjugates. - Molecular and Cellular Biochemistry, 130, 91-101, 1994.
14. KIM S. - Liposomes as carriers of cancer chemotherapy. Current status and future prospects. - Drugs, 46, 618-638, 1993.
15. COUVREUR P., DUBERNET C. and PUISIEUX F. - Controlled drug delivery with nanoparticles: current possibilities and future trends. - Eur. J. Pharm. Biopharm., 41, 2-13, 1995.
16. OKADA H. and TOGUCHI H. - Biodegradable microspheres in drug delivery. - Crit. Rev. Ther. Drug Carr. Sys., 12, 1-99, 1995.
17. GABIZON A., ISACSON R., LIBSON E., KAUFMAN B., UZIELY B., CATANE R., BEN-DOR C.G., RABELLO E., CASS Y., PERETZ T., SULKES A., CHISIN R. and BARENHOLZ Y. -Clinical studies of liposome-encapsulated doxorubicin. - Acta Oncologica, 33, 779-786, 1994.
18. LASIC D.D. - Doxorubicin in sterically stabilized liposomes. -Nature, 380, 561-562, 1996.
19. LASIC D.D. and PAPAHADJOPOULOS D. - Liposomes revisited. - Science, 267, 1275-1276, 1995.
20. WOODLE M.C. - Sterically stabilized liposome therapeutics. -Adv. Drug Del. Rev., 16, 149-165, 1995.
21. OKU N. and NAMBA Y. - Long-circulating liposomes. - Crit. Rev. Ther. Drug Carr. Sys., 11, 231-270, 1994.
22. SATO T. and SUNAMOTO J. - Recent aspects in the use of liposomes in biotechnology and medicine. - Progress in Lipid Research, 31, 345-372, 1992.
23. GHOSE T.I., BLAIR A.H. and KULKARNI P.N. - Preparation of antibody-linked cytotoxic agents. - Methods in Enzymology, 93, 280-333, 1983.
24. MATTSON G., CONKLIN E., DESAI S., NIELANDER G., SAVAGE M.D. and MORGENSEN S. - A practical approach to crosslinking. - Molecular Biology Reports, 17, 167-183, 1993.
25. BRASLAWSKY G.R., KADOW K., KNIPE J., MCGOFF K., EDSON M., KANEKO T. and GREENFIELD R.S. -Adriamycin(hydrazone)-antibody conjugates require internalization and intracellular acid hydrolysis for antitumor activity. - Cancer Immunology Immunotherapy, 33, 367-374, 1991.
26. TRAIL P.A., WILLNER D., KNIPE J., HENDERSON A.J., LASCH S.J., ZOECKLER M.E., TRAILSMITH M.D., DOYLE T.W., DALTON KING H., CASAZZA A.M., BRASLAWSKY G.R., BROWN J., HOFSTEADS. J., GREENFIELD R.S., FIRESTONE R.A., MOSURE K., KADOW K.F., YANG M.B., HELLSTRÖM K.E. and HELLSTRÖM I. - Effect of linker variation on the stability, potency, and efficacy of carcinoma-reactive BR64-doxorubicin immunoconjugates. - Cancer Res., 57, 100-105, 1997.
27. VITETTA E.S. and UHR J.W. - Immunotoxins. - Ann. Rev. Immunol., 3, 197-212, 1985.
28. MONTFORT W., VILLAFRANCA J.E., MONZINGO A.F., ERNST S.R., KATZIN B., RUTENBER E., XUONG N.H., HAMLIN R. and ROBERTUS J.D. - The three-dimensional stru cture of ricin at 2.8 Å. - J. Biol. Chem., 262, 5398-5403, 1987.
29. MORRIS K.N. and WOOL I.G. - Analysis of the contribution of an amphiphilic α-helix to the structure and to the function of ricin A chain. - Proc. Natl. Acad. Sci. USA, 91, 7530-7533, 1994.
30. NEWTON, D.L., WALES R., RICHARDSON P.T., WALBRIDGE S., SAXENA S.K., ACKERMAN E.J., ROBERTS L.M., LORD J.M. and YOULE R.J. - Cell surface and intracellular functions for ricin galactose binding. - J. Biol. Chem., 267, 11917-11922, 1992.
31. UCKUN F.M, MYERS D.E., LEDBETTER J.A., WEE S.L. and VALLERA D.A. - Cell-type-specific cytotoxicity of anti-CD4 and anti-CD8 ricin immunotoxins against human alloreactive T-cell clones. - Blood, 74, 2445-2454, 1989.
32. MYERS D.E., UCKUN F.M, BALL E.D. and VALLERA D.A. -Immunotoxins for ex vivo marrow purging in autologous bone marrow transplantation for acute nonlymphocytic leukemia. -Transplantation, 46, 240-245, 1988.
33. GOLDMACHER V.S., BOURRET L.A., LEVINE B.A., RASMUSSEN R.A., POURSHADI M., LAMBERT J.M. and ANDERSON K.C. - Anti-CD38-blocked ricin: an immunotoxin for the treatment of multiple myeloma. - Blood, 84, 3017-3025, 1994.
34. COLLINSON A.R., LAMBERT J.M., LIU Y., O'DEA C., SHAH S.A., RASMUSSEN R.A. and GOLDMACHER V.S. - Anti-CD6-blocked ricin: an anti-pan T-cell immunotoxin. - Int. J. Immunopharmacol., 16, 37-49, 1994.
35. GROSSBARD M.L., LAMBERT J.M., GOLDMACHER V.S., SPECTOR N.L., KINSELLA J., ELISEO L., CORAL F., TAYLOR J.A., BLATTLER W.A. and EPSTEIN C.L. - Anti-B4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms. - J. Clin. Oncol., 11, 726-737, 1993.
36. SHAH S.A., HALLORAN P.M., FERRIS C.A., LEVINE B.A., BOURRET L.A., GOLDMACHER V.S. and BLATTLER W.A. -Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models. - Cancer Research, 53, 1360-1367, 1993.
37. LAMBERT J.M., MCINTYRE G., GAUTHIER M.N., ZULLO D., RAO V., STEEVES R.M., GOLDMACHER V.S. and BLATTLER W.A. - The galactose-binding sites of the cytotoxic lectin ricin can be chemically blocked in high yield with reactive ligands prepared by chemical modification of glycopeptides containing triantennary N-linked oligosaccharides. - Biochemistry, 30, 3234-3247, 1991.
38. O'CONNOR R., LIU C., FERRIS C.A., GUILD B.C., TEICHER B.A., CORVI C., LIU Y., ARCECI R.J., GOLDMACHER V.S. and LAMBERT J.M. - Anti-B4-blocked ricin synergizes with doxorubicin and etoposide on multidrug-resistant and drug-sensitive tumors. - Blood, 86, 4286-4294, 1995.
39. THORPE P.E., ROSS W.C J., BROWN A.N.F., MYERS C.D., CUMBER A.J., FOXWELL B.M.J. and FORRESTER J.T. -Blockade of the galactose-binding site of ricin by its linkage to antibody. Specific cytotoxic effects of the conjugates. - Eur. J. Biochem., 140, 63-71, 1984.
40. CATTEL L., DELPRINO L., BRUSA P., DOSIO F., COMOGLIO P.M. and PRAT M. - Comparison of blocked and non-blocked ricin-antibody immunotoxins against human gastric carcinoma and colorectal adenocarcinoma cell lines. - Cancer Immunol. Immunother., 27, 233-240, 1988.
41. BRUSA P., PIETRIBIASI F., BUSSOLATI G., DOSIO F., ARIONE R., COMOGLIO P.M., PRAT M. and CATTEL L. -Blocked and not blocked whole-ricin-antibody immunotoxins: intraperitoneal therapy of human tumour xenografted in nude mice. - Cancer Immunol. Immunother., 29, 185-192, 1989.
42. COGLIATI T., BRUSA P., CANEVARI S., CALDERA M., MEZZANZANICA D., DOSIO F., CATTEL L. and COLNAGHI M.I. - Preparation and characterization of blocked and no-blocked conjugates consisting of ricin and a tumor-specific non-internalizing Monoclonal antibody. - Anticancer Res., 11, 417-422, 1991.
43. CATTEL L., BRUSA P., DOSIO F., PACCHIONI D., DELPRINO L. and BUSSOLATI G. - Pharmacokinetic and biodistribution studies of an immunoconjugate directed against human colorectal adenocarcinoma cell line. - J. Chemother., 3, 348-350, 1991.
44. DOSIO F., COGLIATI T., CANEVARI S., MEZZANZANICA D., BRUSA P., DELPRINO L, COLNAGHI M.I. and CATTEL L. -Antibody-toxin conjugate preparation: effects of the linker on activity and stability. - Antibody, Immunoconjugates and Radiopharmaceuticals, 2, 101-115, 1989.
45. BARBIERI L., BATTELLI M.G. and STIRPE F. - Ribosome-inactivating proteins from plants. - Biochimica et Biophysica Acta, 1154, 237-282, 1993.
46. SIEGALL C.B., GAWLAK S.L., CHACE D., WOLF E.A., MIXAN B and MARQUARDT H. - Characterization of ribosome-inactivating proteins isolated from Bryonia dioica and their utility as carcinoma-reactive immunoconjugates. - Bioconj. Chem., 5, 423-429, 1994.
47. SCOTT C.F., GOLDMACHER V.S., LAMBERT J.M., CHAVI R.V.J., BOLENDER S., GAUTHIER M.N. and BLATTLER W.A. - The antileukemic efficacy of an immunotoxin composed of a monoclonal anti-Thy-1 antibody disulfide linked to the ribosome-inactivating protein gelonin. - Cancer Immunol. Immunother., 25, 31-40, 1987.
48. FALINI B., BOLOGNESI A., TAZZARI P.L., BROE M.K., STEIN H., DURKOP H., ANVERSA F., CORNELI P., PIZZOLO G., BARBABIETOLA G., SABATTINI E., PILERI S., MARTELLI M. F. and STIRPE F. - Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin. - Lancet, 339, 1195-1196, 1992.
49. CARLSSON J., DREVIN H. and AXEN R. - Protein thiolation and reversible protein-protein conjugation. - Biochem. J., 173, 723-737, 1978.
50. BOLOGNESI A., BARBIERI L., ABBONDANZA A., FALASCA A.I., CARNICELLI D., BATTELLI M.G. and STIRPE F. -Purification and properties of new ribosome-iriactivating proteins with RNA N-glycosidase activity. - Biochimica et Biophysica Acta, 1087, 293-302, 1990.
51. DELPRINO L., GIACOMOTTI M., DOSIO F., BRUSA P., CERUTI M., GROSA G. and CATTEL L. - Toxin-targeted design for anticancer therapy. I. Synthesis and biological evaluation of new thioimidate heterobifiunctional reagents. - J. Pharm. Sci., 82, 506-512, 1993.
52. STIRPE F., OLSNES S. and PIHL A. - Gelonin, a new inhibitor of protein synthesis, nontoxic to intact cells. Isolation, characterization, and preparation of cytotoxic complexes with concanavalin A. - J. Biolog. Chem., 255, 6947-6953, 1980.
53. SRINIVASAN Y, RAMPRASAD M.P. and SUROLIA A. -Chemical modification studies of gelonin. Involvement of arginine residues in biological activity. - FEBS Letters, 192, 113-118, 1985.
54. SINGH V. and SAIRAM M.R. - Effects of thiolation on the immunoreactivity of the ribosome-inactivating protein gelonin. -Biochem. J., 263, 417-423, 1989
55. PRAT M., MORRA I., BUSSOLATI G. and COMOGLIO P.M. -CAR-3, a monoclonal antibody-defined antigen expressed on human carcinomas. - Cancer Res., 45, 5799-5807, 1985.
56. DELPRINO L., GIACOMOTTI M., DOSIO F., BRUSA P., CERUTI M., GROSA G. and CATTEL L. - Toxin-targeted design for anticancer therapy. 11 : preparation and biological comparison of different chemically linked gelonin-antibody conjugates. - J. Pharm. Sci., 82, 699-704, 1993.
57. THORPE P.E., WALLACE P.M., KNOWLES P.P., RELF M.G., BROWN A.N.F., WATSON G.J., KNYBA R.E., WAWRZYNCZAK E.J. and BLAKEY D.C. - New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo. - Cancer Res., 47, 5924-5931, 1987.
58. WORRELL N.R., CUMBER A.J., PARNELL G.D., MIRZA A., FORRESTER J.A. and ROSS W.C.J.-Effect of linkage variation on pharmacokinetcs of ricin A chain-antibody conjugates in normal rats. - Anti-Cancer Drug Design, 1, 179-188, 1986.
59. GOFF D.A. and CARROLL S.F. - Substituted 2-iminothiolanes: reagents for the preparation of disulfide cross-linked conjugates with increased stability. - Bioconjugate Chemistry, 1, 381-386, 1990.
60. CARROLL S.F., BERNHARD S.L., GOFF D.A., BAUER R.J., LEACH W. and KUNG A.H.C. - Enhanced stability in vitro and in vivo of immunoconjugates prepared with 5-methyl-2-iminothiolane. - Bioconjugate Chemistry, 5, 248-256, 1994.
61. ARPICCO S., DOSIO F., BRUSA P., CROSASSO P. and CATTEL L. - New coupling reagents for the preparation of disulfide cross-linked conjugates with increased stability. -Bioconjugate Chemistry, 8, 327-337, 1997.
62. PARENTE D., RAUCCI P., CELANO B., PACILLI A., ZANONI L., CANEVARI S., ADOBATI E., COLNAGHI M.I., DOSIO F., ARPICCO S., CATTEL L., MELE A. and DE SANTIS R. - Clavin, a type I ribosome-inactivating protein from Aspergillus clavatus IFO 8605. cDNA isolation, heterologous expression and recombinant protein characterization. - Eur. J. Biochem., 239, 272-280, 1996
63. DOSIO F., ARPICCO S., ADOBATI E., CANEVARI S., BRUSA P., DE SANTIS R., PARENTE D., PIGNANELLI P., NEGRI D.R.M., COLNAGHI M.I. and CATTEL L. - Role of cross-linking agents in determining the biochemical and pharmacokinetic properties of Mgr6-clavin immunotoxins. - Bioconjugate Chemistry, 9, 372-381, 1998.
64. DOSIO F., BRUSA P., DELPRINO L., CERUTI M., GROSA G. and CATTEL L. - A new « solid phase » procedure to synthesize immunotoxins (antibody-ribosome inactivating protein conjugates). - II Farmaco, 48, 105-115, 1993.
65. 2 antibody for the delivery of saporin in the treatment of lymphoma.-J. Immunol., 141, 3662-3670, 1988.
66. 2 antibodies for delivering saporin to lymphoma in vitro and in vivo. - Cancer Res., 51, 2353-2361 1991.
67. HASHIMOTO N., TAKATSU K., MASHUO Y., KISHIDA K., HARA T. and HAMAOKA T. - Selective elimination of a B cell subset having acceptor sites for T cell-replacing factor (TRF) with biotinylated antibody to the receptor sites and avidin-ricin-A chain conjugate. - J. Immunol., 132, 129-133, 1984.
68. MEYER B.F., STONER M.L., RAPHAEL C.L., DAVIS R.E. and HERRMANN R.P. - Streptavidin-biotin immunotoxins: a new approach to purging bone marrow. - Exper. Hematol., 19, 710-713, 1991.
69. SPERTI S., MONTANARO L., RAMBELLI F. and ZAMBONI M. - Interaction of α-sarcin and gelonin with cibacron blue. -Bioscience Reports, 6, 901-908, 1986.
70. STIRPE F., BARBIERI L., BATTELLI M.G., SORIA M. and LAPPID. A. - Ribosome inactivating proteins from plants: present status and future prospects. - Biotechnology, 10, 405-412, 1992.
71. DOSIO F., BRUSA P., DELPRINO L., GROSA G., CERUTI M. and CATTEL L. - A new approach in the synthesis of immunotoxins: ribosome inactivating protein noncovalently bound to monoclonal antibody. - J. Pharm. Sci., 83, 206-211. 1994.
72. DOSIO F., BRUSA P., CROSASSO P., FRUTTERO C., BOLOGNESI A. and CATTEL L. - Synthesis of different immunotoxins composed by ribosome inactivating proteins non-covalently bound to monoclonal antibody. - II Farmaco, 51, 477-482, 1996.
73. MALONEY D.G., GRILLO-LOPEZ A.J., WHITE C.A., BODKIN D., SCHILDER R.J. and NEIDHART J.A. - IDEC-C2B8 (rituximab)anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. - Blood, 90, 2188-2195, 1997.
74. BLAKEY D.C. - Drug targeting with monoclonal antibodies. -Reviews in Oncology, 5, 91-97, 1992.
75. REISFELD R.A., YANG H.M., MULLER B., WARGALLA U.C., SCHRAPPE M. and WRASIDLO W. - Promises, problems, and prospects of monoclonal antibody-drug conjugates of cancer therapy. - Antibody, Immunoconjugates and Radio-pharmaceuticals, 2, 217-224, 1989.
76. GOERLACH A., KRAUER K.G., MCKENZIE I.F.C. and PIETERSZ A.G. - In vitro antitumor activity of 2′-deoxy-5-fluorouridine-monoclonal antibody conjugates. - Bioconjugate Chemistry, 2, 96-101, 1991.
77. STARLING J.J., MACIAK R.S., HINSON N.A., NICHOLS C.L., BRIGGS S.L., LAGUZZA B.C., SMITH W. and CORVALAN J.R.F. - In vivo antitumor activity of a panel of four monoclonal antibody-vinca alkaloid immunoconjugates which bind three distinct epitopes of carcinoembryonic antigen. - Bioconjugate Chemistry, 3, 315-322, 1992.
78. DOSIO F., RICCI M., BRUSA P. and CATTEL L. - Antibody-targeted leucinostatin A. - J. Contr. Rel., 32, 37-44, 1994.
79. GHOSE T., BLAIR A.H., KRALOVEC J., MAMMEN M. and UADIA P. - Synthesis and testing of antibody-antifolate conjugates for drug targeting. - In: Antibody-Mediated Delivery Systems, J.D. Rodwell Ed., Marcel Dekker, New York., 1988, pp. 81-84.
80. RUSSELL S.M., KRAUER K.G., MCKENZIE I.F.C. and Pl ETERSZ G. A. - Effect of tumor necrosis factor on the antitumor efficacy and toxicity of aminopterin-monoclonal antibody conjugates: parameters for optimization of therapy. - Cancer Research, 50, 6028-6033, 1990.
81. JOHNSON D.A., BAKER A.L., LAGUZZA B.C., FIX D.V. and GUTOWSKI M.C. - Antitumor activity of L/1C2-4desacetylvinblastine-3-carboxhydrazide immunoconjugate in xenografts. - Cancer Res., 50, 1790-1794, 1990.
82. BRUSA P., DOSIO F., COPPO S., PACCHIONI D., ARPICCO S., CROSASSO P. and CATTEL L. - In vitro and in vivo antitumor activity of immunoconjugates prepared by linking 5-fluorouridine to antiadenocarcinoma monoclonal antibody. - II Farmaco, 52, 71-81, 1997.
83. JAIN R.K. - Physiological barrier to delivery of monoclonal antibodies and other macromolecules in tumors. - Cancer Res., 50 (Suppl.), 814s-819s, 1990.
84. JAIN R.K. and BAXTER L.T. - Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. - Cancer Res., 48, 7022-7032, 1988.
85. FIORE C. - Committee recommends FDA approval of three new drugs for cancer treatment. - Cancer Letters, 24, 1-4, 1998.
86. ROWINSKY E.K. and DONEHOWER R.C. - Paclitaxel (Taxol) - New England J. Med., 332, 1004-1014, 1995.
87. SPENCER C.M. and FAULDS D. - Paclitaxel - Drugs, 48, 794-847, 1994
88. MAEDA H., SEYMOUR L.W. and MIYAMOTO Y. - Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. - Bioconjugate Chemistry, 3, 351-361, 1992.
89. DOSIO F., BRUSA P., CROSASSO P., ARPICCO S. and CATTEL L. - Preparation, characterization and properties in vitro and in vivo of a paclitaxel-albumin conjugate. - J. Contr. Rel., 47, 293-304, 1997.
90. LI C., YU D.F., NEWMAN R.A., CABRAL F., STEPHENS L.C., HUNTER N., MILAS L. and WALLACE S. - Complete regression of well-established tumors using a novel water-soluble poly(L-glutamic acid) paclitaxel conjugate. - Cancer Res., 58, 2404-2409, 1998.
91. FRAIER D., CENACCHI V. and FRIGERIO E. - Determination of a new polymer-bound paclitaxel derivative (PNU 166945), free paclitaxel and 7-epipaclitaxel in dog plasma and urine by reversed-phase high-performance liquid chromatography with UV detection. - J. Chromatog. A, 797, 295-303, 1998.
92. HARASHIMA H. and KIWADA H. - Liposomal targeting and drug delivery: kinetic consideration. - Adv. Drug Del. Rev., 19, 425-444, 1996.
93. LITZINGER D.C. and HUANG L. - Phosphatidylethanolamine liposomes: drug delivery, gene transfer and immunodiagnostic applications. - Biochimica et Biophysica Acta, 1113, 201-227, 1992.
94. ALLEN T.M. and MOASE E.H. - Therapeutic opportunities for targeted liposomal drug delivery. - Adv. Drug Del. Rev., 21, 117-133, 1996.
95. HEATH T.D. and MARTIN F.J. -The development and application of protein-liposome conjugation techniques. - Chemistry and Physics of Lipids, 40, 347-358, 1986.
96. NÄSSANDER U.K., STEERENBERG P.A., DE JONG W.H., VAN OVERVELD W.O.W.M., TE BOEKHORST C.M.E., POELS LG.G, JAP P.H.K. and STORM G. - Design of immunoliposomes directed against human ovarian carcinoma. - Biochimica et Biophysica Acta, 1235, 126-139, 1995.
97. BRENNER D.E. - Intraperitoneal chemotherapy: a review. - J. Clin. Oncol., 4, 1135-1147, 1986.
98. WOLF B.E. and SUGARBAKER P.H. - Intraperitoneal chemotherapy and immunotherapy. - Rec. Res. Cancer Res., 110, 254-273, 1988.
99. STAUBINGER R.M., LOPEZ N.G., DEBS R.J., HONG K. and PAPAHADJOPOULOS D. - Liposome-basec therapy of human ovarian cancer: parameters determining potency of negatively charged and antibody-targeted liposomes. - Cancer Res., 48, 5237-5345, 1988.
100. NÄSSANDER U.K., STEERENBERG P.A., POPPE H., STORM G., POELS, L.G., DE JONG W.H. and CROMMELIN D.J.A. - In vivo targeting of OV-TL 3 immunoliposomes to ascitic ovarian carcinoma cells (OVCAR-3) in athymic nude mice. - Cancer Res, 52, 646-653, 1992.
101. HIRANO K., HUNT C.A., STRUBBE A. and MacGREGOR R.D. - Lymphatic transport of liposome-encapsulated drugs following intraperitoneal administration effect of lipid composition. - Pharm. Res., 2, 271-278, 1985.
102. CROSASSO P., BRUSA P., DOSIO F , ARPICCO S., PACCHIONI D., SCHUBER F. and CATTEL L. - Antitumoral activity of liposomes and immunoliposomes containing 5-fluorouridine prodrugs. - J. Pharm. Sci., 86, 832-839, 1997.